Literature DB >> 22015395

Establishing China's national standards of antigen content and neutralizing antibody responses for evaluation of enterovirus 71 (EV71) vaccines.

Zhenglun Liang1, Qunying Mao, Qiang Gao, Xiuling Li, Chenghong Dong, Xiang Yu, Xin Yao, Fengxiang Li, Weidong Yin, Qihan Li, Xinliang Shen, Junzhi Wang.   

Abstract

Enterovirus 71 (EV71) is a highly infectious agent that causes hand-foot-mouth disease (HFMD) in humans. Effective vaccination against EV71 infection is critically important, given the recent outbreak of HFMD in the Asia-Pacific region, where it has shown significant mortality and morbidity. There is currently no approved anti-viral therapy available to treat the disease. While several vaccine manufacturers are actively developing EV71 vaccines, there are no international reference standards available to conduct quality control on EV71 vaccines or to assess the effectiveness of EV71 vaccines in immunized populations. In the current report, antigen reference standard based on the C4 subtype of the EV71 vaccine strain was developed. In addition, neutralizing antibody (NTAb) reference panels were analyzed and standards with various neutralizing titers were selected. These reference antigens were used to calibrate vaccine samples from several producers and found that five EV71 antigens and the national reference standards showed good linearity and parallelism. Moreover, mice immunized with various vaccines at doses standardized by these national references showed comparable NTAb responses. Finally, the national NTAb reference panels were found to effectively reduce assay discrepancy between different labs. Taken together, these national reference standards are highly valuable for the standardization and evaluation of EV71 vaccines.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22015395     DOI: 10.1016/j.vaccine.2011.10.018

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  32 in total

1.  Type I interferon related genes are common genes on the early stage after vaccination by meta-analysis of microarray data.

Authors:  Junnan Zhang; Jie Shao; Xing Wu; Qunying Mao; Yiping Wang; Fan Gao; Wei Kong; Zhenglun Liang
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

2.  Development of a sandwich ELISA for the quantification of enterovirus 71.

Authors:  Shujun Ma; Qunying Mao; Zhenglun Liang; Cuijuan Zhang; Wenxing Yang; Zhe Sun; Haijiang Zhang; Xinliang Shen; Shengli Bi; Le Sun
Journal:  Cytotechnology       Date:  2013-06-02       Impact factor: 2.058

3.  Immunogenicity, safety, and lot consistency of a novel inactivated enterovirus 71 vaccine in Chinese children aged 6 to 59 months.

Authors:  Yue-Mei Hu; Xu Wang; Jun-Zhi Wang; Ling Wang; Yong-Jie Zhang; Lin Chang; Zheng-Lun Liang; Jie-Lai Xia; Qi-Gang Dai; Ya-Ling Hu; Qun-Ying Mao; Feng-Cai Zhu; Yu-Fei Song; Fan Gao; Jiang-Ting Chen
Journal:  Clin Vaccine Immunol       Date:  2013-10-09

4.  Immunogenicity and protective efficacy of an EV71 virus-like particle vaccine against lethal challenge in newborn mice.

Authors:  Shiyang Sun; Fan Gao; Qunying Mao; Jie Shao; Liping Jiang; Dawei Liu; Yiping Wang; Xin Yao; Xing Wu; Bo Sun; Dandan Zhao; Youlei Ma; Jingcai Lu; Wei Kong; Chunlai Jiang; Zhenglun Liang
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

5.  Validation and evaluation of serological correlates of protection for inactivated enterovirus 71 vaccine in children aged 6-35 months.

Authors:  Pengfei Jin; Jingxin Li; Xuefeng Zhang; Fangyue Meng; Yang Zhou; Xuejun Yao; Zhengkai Gan; Fengcai Zhu
Journal:  Hum Vaccin Immunother       Date:  2016-01-11       Impact factor: 3.452

6.  Clinical evaluation for batch consistency of an inactivated enterovirus 71 vaccine in a large-scale phase 3 clinical trial.

Authors:  Yi-Juan Chen; Fan-Yue Meng; Qunying Mao; Jing-Xin Li; Hua Wang; Zheng-Lun Liang; Yun-Tao Zhang; Fan Gao; Qing-Hua Chen; Yuemei Hu; Zi-Jun Ge; Xin Yao; Hui-Jie Guo; Feng-Cai Zhu; Xiu-Ling Li
Journal:  Hum Vaccin Immunother       Date:  2014-03-14       Impact factor: 3.452

7.  Development and characterization of an enterovirus 71 (EV71) virus-like particles (VLPs) vaccine produced in Pichia pastoris.

Authors:  Zhijian Yang; Fan Gao; Xiaoliang Wang; Likang Shi; Zheng Zhou; Yuanxiang Jiang; Xinxing Ma; Chao Zhang; Chenliang Zhou; Xianfang Zeng; Ge Liu; Jiang Fan; Qunying Mao; Li Shi
Journal:  Hum Vaccin Immunother       Date:  2019-08-15       Impact factor: 3.452

8.  The compatibility of inactivated-Enterovirus 71 vaccination with Coxsackievirus A16 and Poliovirus immunizations in humans and animals.

Authors:  Qunying Mao; Yiping Wang; Jie Shao; Zhifang Ying; Fan Gao; Xin Yao; Changgui Li; Qiang Ye; Miao Xu; Rongcheng Li; Fengcai Zhu; Zhenglun Liang
Journal:  Hum Vaccin Immunother       Date:  2015-02-25       Impact factor: 3.452

Review 9.  Progress on the research and development of human enterovirus 71 (EV71) vaccines.

Authors:  Zhenglun Liang; Qunying Mao; Fan Gao; Junzhi Wang
Journal:  Front Med       Date:  2012-12-17       Impact factor: 4.592

Review 10.  Seroprevalence of Enterovirus 71 Antibody Among Children in China: A Systematic Review and Meta-analysis.

Authors:  Bingyi Yang; Peng Wu; Joseph T Wu; Eric H Y Lau; Gabriel M Leung; Hongjie Yu; Benjamin J Cowling
Journal:  Pediatr Infect Dis J       Date:  2015-12       Impact factor: 2.129

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.